Development status
Potential First-in-Class
& Best-in-Class NASH Drug
Patented FGF21 design
& Manufacturing method
Experienced & Validated Team in
the protein research field
- Substantial potential market opportunity
- Differentiated mechanism of action
- Strong efficacy data of FGF21 including:
- The levels of hepatic triglycerides and lipids
- The degree of vacuolization of liver
- Validated Immunogenicity
- Five point-mutations for high affinity toward β-Klotho and enhanced receptor activation
- The ever-first findings of
- The temperature-responsive structural reversibility of FGF21 and
- Heating-based purification of active FGF21
- These findings can be applied to FGF21 analogs that are under therapeutic development
- Sun-shin Cha (a full professor at Ewha Woman
University) leads a competitive protein research group - Three LO experiences for β-lactamase inhibitors, human DJ-1 (park7), and FGF21 (to TODD) in Korea
- About 130 publications including Nature, Immunity, Nature Genetics, Nature Chemical Biology, Nature Communications, EMBO J, PNAS, Angewandte Chemie, Nucleic Acid Research, JBC, etc.